Yousif Capital Management LLC Sells 1,013 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Yousif Capital Management LLC cut its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 45,841 shares of the medical research company’s stock after selling 1,013 shares during the quarter. Yousif Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $24,332,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. International Assets Investment Management LLC grew its stake in Thermo Fisher Scientific by 43.5% during the 3rd quarter. International Assets Investment Management LLC now owns 1,626 shares of the medical research company’s stock worth $810,000 after buying an additional 493 shares during the last quarter. Arkadios Wealth Advisors increased its holdings in shares of Thermo Fisher Scientific by 33.3% during the third quarter. Arkadios Wealth Advisors now owns 896 shares of the medical research company’s stock valued at $454,000 after acquiring an additional 224 shares in the last quarter. Wedge Capital Management L L P NC boosted its stake in Thermo Fisher Scientific by 8.3% in the 3rd quarter. Wedge Capital Management L L P NC now owns 740 shares of the medical research company’s stock worth $375,000 after purchasing an additional 57 shares in the last quarter. Summit Global Investments grew its holdings in shares of Thermo Fisher Scientific by 27.8% during the third quarter. Summit Global Investments now owns 1,392 shares of the medical research company’s stock valued at $704,000 after buying an additional 303 shares during the last quarter. Finally, Naples Global Advisors LLC increased its position in shares of Thermo Fisher Scientific by 37.3% in the 3rd quarter. Naples Global Advisors LLC now owns 755 shares of the medical research company’s stock valued at $382,000 after acquiring an additional 205 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, Director Debora L. Spar sold 164 shares of Thermo Fisher Scientific stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the completion of the sale, the director now directly owns 1,207 shares in the company, valued at $660,192.79. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the completion of the transaction, the director now directly owns 1,207 shares in the company, valued at $660,192.79. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total value of $5,556,300.00. Following the completion of the sale, the chief executive officer now owns 49,155 shares in the company, valued at approximately $27,311,992.65. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 50,277 shares of company stock worth $28,513,384. Company insiders own 0.32% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Barclays lowered Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and increased their price objective for the company from $475.00 to $555.00 in a report on Wednesday, January 24th. Raymond James raised their price target on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research report on Thursday, February 1st. HSBC upped their price objective on shares of Thermo Fisher Scientific from $630.00 to $660.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. Citigroup began coverage on shares of Thermo Fisher Scientific in a report on Monday, March 18th. They set a “neutral” rating and a $620.00 target price for the company. Finally, The Goldman Sachs Group lifted their price target on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Five investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $604.69.

Thermo Fisher Scientific Trading Up 4.9 %

Shares of NYSE TMO traded up $26.72 during trading on Tuesday, hitting $575.10. 2,543,876 shares of the company were exchanged, compared to its average volume of 1,562,261. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.39 and a current ratio of 1.75. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $603.82. The company has a fifty day moving average price of $572.03 and a 200-day moving average price of $528.72. The firm has a market capitalization of $219.52 billion, a PE ratio of 37.22, a P/E/G ratio of 2.30 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, beating the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The company had revenue of $10.89 billion for the quarter, compared to analyst estimates of $10.73 billion. During the same period in the previous year, the business posted $5.40 EPS. Thermo Fisher Scientific’s revenue was down 4.9% on a year-over-year basis. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.51 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were issued a dividend of $0.39 per share. The ex-dividend date was Thursday, March 14th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.10%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.